Thompson Siegel & Walmsley LLC Has $13.73 Million Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Thompson Siegel & Walmsley LLC raised its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 17.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 230,159 shares of the specialty pharmaceutical company’s stock after acquiring an additional 34,416 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in ANI Pharmaceuticals were worth $13,731,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Innealta Capital LLC acquired a new position in ANI Pharmaceuticals during the 2nd quarter valued at about $65,000. Ridgewood Investments LLC bought a new position in ANI Pharmaceuticals during the second quarter valued at about $85,000. SG Americas Securities LLC bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $106,000. XTX Topco Ltd purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at $207,000. Finally, O Shaughnessy Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals in the first quarter worth about $218,000. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Trading Down 1.1 %

Shares of ANI Pharmaceuticals stock opened at $55.10 on Thursday. The company’s fifty day simple moving average is $58.35 and its two-hundred day simple moving average is $61.07. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business’s revenue was up 12.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.05 earnings per share. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the topic of several recent research reports. Piper Sandler began coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price on the stock. Truist Financial increased their price objective on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Raymond James lifted their target price on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a report on Wednesday, September 18th. HC Wainwright reissued a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.